NO328898B1 - Stabile, flytende farmasoytiske formuleringer av botulinumtoksin, samt anvendelse derav. - Google Patents

Stabile, flytende farmasoytiske formuleringer av botulinumtoksin, samt anvendelse derav.

Info

Publication number: NO328898B1
Authority: NO; Norway
Prior art keywords: stable; pharmaceutical formulations; botulinum toxin; liquid pharmaceutical; liquid
Prior art date: 1998-09-11

Application number

NO20011207A

Other languages

English (en)

Norwegian (no)

Other versions

NO20011207D0 (no

NO20011207L (no

Inventor

Elizabeth Moyer

Pamela Hirtzer

Original Assignee

Solstice Neurosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-11

Filing date

2001-03-09

Publication date

2010-06-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22277018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO328898(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-03-09 Application filed by Solstice Neurosciences Inc filed Critical Solstice Neurosciences Inc

2001-03-09 Publication of NO20011207D0 publication Critical patent/NO20011207D0/no

2001-05-09 Publication of NO20011207L publication Critical patent/NO20011207L/no

2010-06-07 Publication of NO328898B1 publication Critical patent/NO328898B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Psychiatry (AREA)
Birds (AREA)
Rheumatology (AREA)
Gerontology & Geriatric Medicine (AREA)
Pregnancy & Childbirth (AREA)
Psychology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Cardiology (AREA)
Otolaryngology (AREA)
Heart & Thoracic Surgery (AREA)

NO20011207A 1998-09-11 2001-03-09 Stabile, flytende farmasoytiske formuleringer av botulinumtoksin, samt anvendelse derav. NO328898B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9987098P	1998-09-11	1998-09-11
PCT/US1999/020912 WO2000015245A2 (fr)	1998-09-11	1999-09-09	Formulations liquides stables de la toxine de botulinum

Publications (3)

Publication Number	Publication Date
NO20011207D0 NO20011207D0 (no)	2001-03-09
NO20011207L NO20011207L (no)	2001-05-09
NO328898B1 true NO328898B1 (no)	2010-06-07

Family

ID=22277018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20011207A NO328898B1 (no)	1998-09-11	2001-03-09	Stabile, flytende farmasoytiske formuleringer av botulinumtoksin, samt anvendelse derav.

Country Status (40)

Country	Link
US (2)	US7211261B1 (fr)
EP (1)	EP1112082B2 (fr)
JP (4)	JP4557426B2 (fr)
KR (1)	KR100699756B1 (fr)
CN (1)	CN100438905C (fr)
AP (1)	AP1591A (fr)
AR (1)	AR022671A1 (fr)
AT (1)	ATE221386T1 (fr)
AU (1)	AU755556C (fr)
BG (1)	BG65555B1 (fr)
BR (1)	BR9913585A (fr)
CA (1)	CA2342243C (fr)
CO (1)	CO5170497A1 (fr)
CU (1)	CU23251A3 (fr)
DE (1)	DE69902396T3 (fr)
DK (1)	DK1112082T4 (fr)
EA (1)	EA003367B1 (fr)
EE (1)	EE200100140A (fr)
ES (1)	ES2181473T5 (fr)
GE (1)	GEP20032946B (fr)
HR (1)	HRP20010259B1 (fr)
HU (1)	HUP0103638A3 (fr)
ID (1)	ID28824A (fr)
IL (2)	IL141564A0 (fr)
IS (1)	IS2381B (fr)
LT (1)	LT4959B (fr)
LV (1)	LV12684B (fr)
NO (1)	NO328898B1 (fr)
NZ (1)	NZ509349A (fr)
PL (1)	PL200926B1 (fr)
PT (1)	PT1112082E (fr)
RS (1)	RS50344B (fr)
SA (1)	SA99200566B1 (fr)
SI (2)	SI1112082T1 (fr)
SK (1)	SK286919B6 (fr)
TR (1)	TR200100728T2 (fr)
TW (1)	TW574036B (fr)
UA (1)	UA72477C2 (fr)
WO (1)	WO2000015245A2 (fr)
ZA (1)	ZA200101709B (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE215832T1 (de) *	1994-05-09	2002-04-15	William J Binder	Botulinumtoxin zur reduktion von migraine - kopfschmerzen
TW574036B (en) *	1998-09-11	2004-02-01	Elan Pharm Inc	Stable liquid compositions of botulinum toxin
US20120238504A1 (en) *	1998-09-11	2012-09-20	Solstice Neurosciences, Llc	Stable Formulations of Botulinum Toxin in Hydrogels
DE19925739A1 (de) *	1999-06-07	2000-12-21	Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh	Therapeutikum mit einem Botulinum-Neurotoxin
US7838007B2 (en)	1999-12-07	2010-11-23	Allergan, Inc.	Methods for treating mammary gland disorders
US7838008B2 (en)	1999-12-07	2010-11-23	Allergan, Inc.	Methods for treating diverse cancers
US8632785B2 (en) *	2000-02-08	2014-01-21	Allergan, Inc.	Clostridial toxin pharmaceutical composition containing a gelatin fragment
ES2368061T3 (es) *	2000-02-08	2011-11-14	Allergan, Inc.	Composiciones farmacéuticas de toxina botulínica.
US20030118598A1 (en) *	2000-02-08	2003-06-26	Allergan, Inc.	Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) *	2000-02-08	2006-11-30	Allergan, Inc.	Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) *	2000-02-08	2010-08-24	Allergan, Inc.	Reduced toxicity Clostridial toxin pharmaceutical compositions
US6821520B2 (en)	2000-02-15	2004-11-23	Allergan, Inc.	Clostridial toxin therapy for Hashimoto's thyroiditis
ITUD20010002A1 (it) *	2001-01-05	2002-07-05	Univ Degli Studi Udine	Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
CA2369810C (fr) *	2002-01-30	2007-08-07	1474791 Ontario Limited	Methode de traitement de la douleur
US7140371B2 (en)	2002-03-14	2006-11-28	Allergan, Inc.	Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en)	2002-03-14	2004-02-10	Allergan, Inc.	Method for determining effect of a clostridial toxin upon a muscle
JPWO2003082315A1 (ja) *	2002-03-29	2005-07-28	財団法人化学及血清療法研究所	筋緊張亢進疾患治療剤
US7691394B2 (en)	2002-05-28	2010-04-06	Botulinum Toxin Research Associates, Inc.	High-potency botulinum toxin formulations
US20040009180A1 (en) *	2002-07-11	2004-01-15	Allergan, Inc.	Transdermal botulinum toxin compositions
CA2854831C (fr)	2002-11-21	2016-08-30	Ira Sanders	Traitement de la reaction physiologique d'un mammifere d'anticorps ige presents dans ledit mammifere en contact avec l'antigene correspondant
JP2006519761A (ja) *	2002-12-20	2006-08-31	ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド	改善された薬学的ボツリヌス毒素組成物
US8071550B2 (en)	2003-03-03	2011-12-06	Allergan, Inc.	Methods for treating uterine disorders
EP1599220B1 (fr) *	2003-03-06	2013-07-17	Botulinum Toxin Research Associates, Inc.	Selection de patients a sensibilite accrue a la toxine botulique
WO2004078201A1 (fr) *	2003-03-06	2004-09-16	Botulinum Toxin Research Associates, Inc.	Traitement des cephalees et des douleurs faciales chroniques associees a la sinusite au moyen de toxine botulinique
US6838434B2 (en) *	2003-05-02	2005-01-04	Allergan, Inc.	Methods for treating sinus headache
US7220422B2 (en) *	2003-05-20	2007-05-22	Allergan, Inc.	Methods and compositions for treating eye disorders
US8609112B2 (en)	2003-10-29	2013-12-17	Allergan, Inc.	Botulinum toxin treatments of depression
US8617572B2 (en)	2003-10-29	2013-12-31	Allergan, Inc.	Botulinum toxin treatments of depression
US8609113B2 (en)	2003-10-29	2013-12-17	Allergan, Inc.	Botulinum toxin treatments of depression
US8734810B2 (en) *	2003-10-29	2014-05-27	Allergan, Inc.	Botulinum toxin treatments of neurological and neuropsychiatric disorders
US9211248B2 (en)	2004-03-03	2015-12-15	Revance Therapeutics, Inc.	Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150568A1 (en)	2004-03-03	2009-03-30	Revance Therapeutics Inc	Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN101083907B (zh)	2004-03-03	2012-10-10	雷文斯治疗公司	用于局部诊断剂和治疗剂运输的组合物和方法
WO2006020208A2 (fr)	2004-07-26	2006-02-23	Merz Pharma Gmbh & Co. Kgaa	Composition therapeutique avec neurotoxine botulique
US7179474B2 (en)	2004-09-03	2007-02-20	Allergan, Inc.	Methods for treating a buttock deformity
US7429386B2 (en)	2004-09-03	2008-09-30	Allergan, Inc.	Stretch mark treatment
US8192979B2 (en)	2005-01-03	2012-06-05	Botulinum Toxin Research Associates, Inc.	Compositions, methods and devices for preparing less painful Botulinum toxin formulations
AU2006218431B2 (en)	2005-03-03	2012-12-06	Revance Therapeutics, Inc.	Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7419675B2 (en)	2005-05-26	2008-09-02	Allergan, Inc.	Method for treating peritoneal adhesions
US8323666B2 (en)	2005-08-01	2012-12-04	Allergan, Inc.	Botulinum toxin compositions
US8137677B2 (en)	2005-10-06	2012-03-20	Allergan, Inc.	Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en)	2005-10-06	2012-05-01	Allergan, Inc.	Animal protein-free pharmaceutical compositions
DE102006019447A1 (de) *	2006-04-24	2007-10-25	Dressler, Dirk, Dr.	Markierung von Botulinum Toxin
AR061669A1 (es) *	2006-06-29	2008-09-10	Merz Pharma Gmbh & Co Kgaa	Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en)	2006-06-29	2020-10-06	Merz Pharma Gmbh & Co. Kgaa	High frequency application of botulinum toxin therapy
JP2010528999A (ja) *	2007-06-01	2010-08-26	メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー	ボツリヌストキシンの神経毒成分に基づいた、温度安定な筋弛緩薬を固体形態で供給する方法
EP2048156A1 (fr) *	2007-10-12	2009-04-15	Merz Pharma GmbH & Co.KGaA	Procédé pour fournir un relaxant musculaire à température stable sur la base d'un composant neurotoxique de toxine botulique
US9107815B2 (en)	2008-02-22	2015-08-18	Allergan, Inc.	Sustained release poloxamer containing pharmaceutical compositions
US20100034854A1 (en) *	2008-08-05	2010-02-11	Solstice Neurosciences, Inc.	Compositions of activated botulinum holotoxin type B (150 KD)
EP2315598A1 (fr) *	2008-08-05	2011-05-04	Solstice Neurosciences, Inc.	Compositions de toxine botulinique activée de type b
US20100112006A1 (en) *	2008-11-03	2010-05-06	Solstice Neurosciences, Inc.	Compositions of activated botulinum holotoxin type B (150 kD)
US20100112005A1 (en) *	2008-11-03	2010-05-06	Solstice Neurosciences, Inc.	Compositions of activated botulinum toxin type B
US20100124559A1 (en) *	2008-11-20	2010-05-20	Allergan, Inc.	Early Treatment and Prevention of Increased Muscle Tonicity
WO2010096134A1 (fr)	2008-12-04	2010-08-26	Botulinum Toxin Research Associates, Inc.	Formulation de toxine botulique à durée de vie prolongée pour utilisation chez un humain ou un mammifère
DK2379104T3 (en)	2008-12-31	2018-04-30	Revance Therapeutics Inc	Injectable botulinum toxin formulations
EP2248518B1 (fr) *	2009-04-17	2013-01-16	Merz Pharma GmbH & Co. KGaA	Formulation pour stabiliser des protéines, des peptides et ses mélanges.
US9340587B2 (en)	2009-06-25	2016-05-17	Revance Therapeutics, Inc.	Albumin-free botulinum toxin formulations
CA2763692A1 (fr)	2009-07-02	2011-01-06	Merz Pharma Gmbh & Co. Kgaa	Neurotoxines presentant une activite biologique raccourcie
AU2010310749B2 (en)	2009-10-21	2016-02-11	Revance Therapeutics, Inc.	Methods and systems for purifying non-complexed botulinum neurotoxin
RU2440812C1 (ru) *	2010-05-27	2012-01-27	ФГУ "НКЦ Оториноларингологии" Федерального медико-биологического агентства России	Способ лечения гипотонусных дисфоний
KR20230007537A (ko) *	2011-01-24	2023-01-12	안테리오스, 인코퍼레이티드	나노입자 조성물, 이의 제형, 및 그의 용도
HK1199890A1 (en)	2011-11-09	2015-07-24	Merz Pharma Gmbh & Co. Kgaa	Neurotoxins exhibiting shortened biological activity
US9393291B2 (en)	2012-04-12	2016-07-19	Botulinum Toxin Research Associates, Inc.	Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
MX370929B (es)	2012-10-28	2020-01-08	Revance Therapeutics Inc	Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
RU2535115C1 (ru)	2013-05-15	2014-12-10	Бости Трейдинг Лтд	Фармацевтический состав, содержащий нейротоксин ботулина
US11484580B2 (en)	2014-07-18	2022-11-01	Revance Therapeutics, Inc.	Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en)	2014-07-18	2018-02-27	Revance Therapeutics, Inc.	Topical ocular preparation of botulinum toxin for use in ocular surface disease
SG11201701619TA (en)	2014-09-02	2017-03-30	American Silver Llc	Botulinum toxin and colloidal silver particles
WO2016102068A1 (fr) *	2014-12-23	2016-06-30	Merz Pharma Gmbh & Co. Kgaa	Récipient pré-rempli de toxine botulinique
CN107206175B (zh)	2015-02-03	2021-06-01	莫茨制药有限及两合公司	肉毒杆菌毒素预填充式容器
DK3679946T3 (da) *	2016-05-27	2022-02-07	Ipsen Biopharm Ltd	Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin
WO2018038301A1 (fr) *	2016-08-26	2018-03-01	Hugel Inc.	Formulation liquide stabilisée de toxine botulique et procédé pour sa préparation
SI3432916T1 (sl)	2016-09-13	2020-01-31	Allergan, Inc.	Stabilizirani ne-protein klostridijski toksin sestavki
MX2019005833A (es)	2016-11-21	2019-10-30	Eirion Therapeutics Inc	Administracion transdermica de agentes grandes.
KR101744900B1 (ko) *	2017-01-20	2017-06-08	주식회사 대웅	보툴리눔 독소를 포함하는 안정한 액상 조성물
CN110996979A (zh) *	2017-05-18	2020-04-10	雷文斯治疗公司	颈肌张力障碍的治疗方法
KR102063475B1 (ko)	2018-02-22	2020-01-09	주식회사 에이비바이오	보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
GB201815844D0 (en)	2018-09-28	2018-11-14	Ipsen Biopharm Ltd	Therapeutic & comestic uses of botulinum neurotoxin serotype e
EP3863589B1 (fr)	2018-10-08	2025-12-03	Merz Pharma GmbH & Co. KGaA	Flacon pré-rempli de toxine botulique

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3522247A (en) *	1967-11-07	1970-07-28	Pfizer & Co C	2-amino-6,7-disubstituted-4h-1,3-benzothiazine-4-ones as bronchodilators
US4932936A (en)	1988-01-29	1990-06-12	Regents Of The University Of Minnesota	Method and device for pharmacological control of spasticity
US5053005A (en)	1989-04-21	1991-10-01	Gary E. Borodic	Chemomodulation of curvature of the juvenile spine
US5919665A (en) *	1989-10-31	1999-07-06	Ophidian Pharmaceuticals, Inc.	Vaccine for clostridium botulinum neurotoxin
US5183462A (en) *	1990-08-21	1993-02-02	Associated Synapse Biologics	Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en)	1991-09-24	1991-11-06	Graham Herbert K	Method and compositions for the treatment of cerebral palsy
AU4646393A (en) †	1992-06-23	1994-01-24	Interactive Biologics Associates	Pharmaceutical composition containing botulinum b complex
EP0593176A3 (fr) *	1992-09-28	1995-03-01	Wisconsin Alumni Res Found	Compositions pharmaceutiques contenant la toxine de botulinum et procédé de préparation.
DE69432299T2 (de)	1993-06-10	2003-12-11	Allergan, Inc.	Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
DE69435253D1 (de)	1993-06-10	2009-12-31	Allergan Inc	Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
GB9315306D0 (en)	1993-07-23	1993-09-08	Smithkline Beecham Corp	Methods
US5437291A (en) *	1993-08-26	1995-08-01	Univ Johns Hopkins	Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) *	1993-12-28	2005-12-13	Allergan, Inc.	Method for treating secretions and glands using botulinum toxin
DE69434540T2 (de)	1993-12-28	2009-06-18	Allergan, Inc., Irvine	Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
US5766605A (en)	1994-04-15	1998-06-16	Mount Sinai School Of Medicine Of The City University Of New York	Treatment of autonomic nerve dysfunction with botulinum toxin
ATE215832T1 (de)	1994-05-09	2002-04-15	William J Binder	Botulinumtoxin zur reduktion von migraine - kopfschmerzen
AU2907695A (en) *	1994-08-08	1996-03-07	Wisconsin Alumni Research Foundation	Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5756468A (en) *	1994-10-13	1998-05-26	Wisconsin Alumni Research Foundation	Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) *	1994-10-13	1996-04-30	Wisconsin Alumni Research Foundation	Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5562899A (en)	1995-02-28	1996-10-08	Gerber; Allen	Medical prevention of lacerations to the vagina and perineum
US6136551A (en) *	1995-04-24	2000-10-24	Allergan, Inc.	Assay for detecting the presence of botulinum toxin neutralizing antibodies in a patient serum sample
DK0773788T3 (da) *	1995-06-06	2003-09-01	Allergan Inc	Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
US5721215A (en)	1996-03-20	1998-02-24	Allergan	Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) *	1996-07-08	2004-03-02	University Of Massachusetts	Proteins within the type E botulinum neurotoxin complex
CN1057430C (zh) *	1996-10-09	2000-10-18	崔生发	一种生物化学杀鼠剂
TW574036B (en) *	1998-09-11	2004-02-01	Elan Pharm Inc	Stable liquid compositions of botulinum toxin
US6146902A (en) *	1998-12-29	2000-11-14	Aventis Pasteur, Inc.	Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6113915A (en)	1999-10-12	2000-09-05	Allergan Sales, Inc.	Methods for treating pain
US6139845A (en)	1999-12-07	2000-10-31	Allergan Sales, Inc.	Method for treating cancer with a neurotoxin
ES2368061T3 (es) *	2000-02-08	2011-11-14	Allergan, Inc.	Composiciones farmacéuticas de toxina botulínica.
US20030118598A1 (en) *	2000-02-08	2003-06-26	Allergan, Inc.	Clostridial toxin pharmaceutical compositions
US6358513B1 (en)	2000-02-15	2002-03-19	Allergan Sales, Inc.	Method for treating Hashimoto's thyroiditis
US6464986B1 (en) *	2000-04-14	2002-10-15	Allegan Sales, Inc.	Method for treating pain by peripheral administration of a neurotoxin
US20080096238A1 (en) *	2004-03-30	2008-04-24	Alcon, Inc.	High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
BRPI0508374A (pt) *	2005-03-03	2007-07-31	Allergan Inc	meios para bactéria clostrìdio e processo para obtenção de uma toxina clostrìdica
JP2008535486A (ja)	2005-03-15	2008-09-04	アラーガン、インコーポレイテッド	クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素
US20080118532A1 (en) *	2006-06-01	2008-05-22	Atassi M Zouhair	Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin b peptides

1999
- 1999-08-31 TW TW88114941A patent/TW574036B/zh active
- 1999-09-07 SA SA99200566A patent/SA99200566B1/ar unknown
- 1999-09-09 WO PCT/US1999/020912 patent/WO2000015245A2/fr not_active Ceased
- 1999-09-09 PL PL347069A patent/PL200926B1/pl not_active IP Right Cessation
- 1999-09-09 PT PT99945649T patent/PT1112082E/pt unknown
- 1999-09-09 NZ NZ509349A patent/NZ509349A/en not_active IP Right Cessation
- 1999-09-09 KR KR1020017003032A patent/KR100699756B1/ko not_active Expired - Fee Related
- 1999-09-09 JP JP2000569829A patent/JP4557426B2/ja not_active Expired - Lifetime
- 1999-09-09 SI SI9930126T patent/SI1112082T1/xx unknown
- 1999-09-09 AT AT99945649T patent/ATE221386T1/de active
- 1999-09-09 BR BR9913585-0A patent/BR9913585A/pt not_active Application Discontinuation
- 1999-09-09 AR ARP990104540A patent/AR022671A1/es unknown
- 1999-09-09 EP EP99945649A patent/EP1112082B2/fr not_active Expired - Lifetime
- 1999-09-09 SI SI9920081A patent/SI20566B/sl not_active IP Right Cessation
- 1999-09-09 IL IL14156499A patent/IL141564A0/xx unknown
- 1999-09-09 ES ES99945649T patent/ES2181473T5/es not_active Expired - Lifetime
- 1999-09-09 AU AU58214/99A patent/AU755556C/en not_active Ceased
- 1999-09-09 TR TR2001/00728T patent/TR200100728T2/xx unknown
- 1999-09-09 US US09/393,590 patent/US7211261B1/en not_active Expired - Lifetime
- 1999-09-09 CO CO99057166A patent/CO5170497A1/es not_active Application Discontinuation
- 1999-09-09 RS YUP-190/01A patent/RS50344B/sr unknown
- 1999-09-09 AP APAP/P/2001/002108A patent/AP1591A/en active
- 1999-09-09 CA CA2342243A patent/CA2342243C/fr not_active Expired - Lifetime
- 1999-09-09 HU HU0103638A patent/HUP0103638A3/hu unknown
- 1999-09-09 CN CNB998107395A patent/CN100438905C/zh not_active Expired - Fee Related
- 1999-09-09 DE DE69902396T patent/DE69902396T3/de not_active Expired - Lifetime
- 1999-09-09 EE EEP200100140A patent/EE200100140A/xx unknown
- 1999-09-09 DK DK99945649.4T patent/DK1112082T4/da active
- 1999-09-09 GE GEAP19995844A patent/GEP20032946B/en unknown
- 1999-09-09 EA EA200100337A patent/EA003367B1/ru not_active IP Right Cessation
- 1999-09-09 SK SK313-2001A patent/SK286919B6/sk not_active IP Right Cessation
- 1999-09-09 UA UA2001042366A patent/UA72477C2/uk unknown
- 1999-09-09 HR HR20010259A patent/HRP20010259B1/xx not_active IP Right Cessation
- 1999-09-09 ID IDW20010592A patent/ID28824A/id unknown
2001
- 2001-01-31 IS IS5836A patent/IS2381B/is unknown
- 2001-02-21 IL IL141564A patent/IL141564A/en not_active IP Right Cessation
- 2001-02-28 ZA ZA200101709A patent/ZA200101709B/en unknown
- 2001-03-09 NO NO20011207A patent/NO328898B1/no not_active IP Right Cessation
- 2001-03-12 CU CU20010063A patent/CU23251A3/es not_active IP Right Cessation
- 2001-04-10 BG BG105435A patent/BG65555B1/bg unknown
- 2001-04-10 LT LT2001041A patent/LT4959B/lt not_active IP Right Cessation
- 2001-04-10 LV LV010056A patent/LV12684B/xx unknown
2007
- 2007-03-08 US US11/683,628 patent/US8173138B2/en not_active Expired - Fee Related
- 2007-03-27 JP JP2007083103A patent/JP2007169301A/ja not_active Withdrawn
2010
- 2010-02-26 JP JP2010043514A patent/JP5270594B2/ja not_active Expired - Lifetime
2013
- 2013-02-28 JP JP2013039884A patent/JP2013144691A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
IL141564A0 (en)	2002-03-10
RS50344B (sr)	2009-11-10
US20070148189A1 (en)	2007-06-28
WO2000015245A3 (fr)	2000-06-08
AP2001002108A0 (en)	2001-03-31
BG65555B1 (bg)	2008-12-30
EA003367B1 (ru)	2003-04-24
ES2181473T3 (es)	2003-02-16
SI20566B (sl)	2008-08-31
SK286919B6 (sk)	2009-07-06
SK3132001A3 (en)	2001-10-08
CU23251A3 (es)	2007-12-17
AU755556B2 (en)	2002-12-12
PL347069A1 (en)	2002-03-11
IL141564A (en)	2009-08-03
AU755556C (en)	2005-12-15
NZ509349A (en)	2003-08-29
ATE221386T1 (de)	2002-08-15
US7211261B1 (en)	2007-05-01
TW574036B (en)	2004-02-01
SI1112082T1 (en)	2002-12-31
ID28824A (id)	2001-07-05
PL200926B1 (pl)	2009-02-27
SA99200566B1 (ar)	2006-09-20
DK1112082T4 (da)	2010-05-31
TR200100728T2 (tr)	2001-08-21
HRP20010259B1 (hr)	2007-11-30
JP2013144691A (ja)	2013-07-25
LV12684B (lv)	2001-10-20
JP2010138186A (ja)	2010-06-24
YU19001A (sh)	2005-06-10
SI20566A (sl)	2001-12-31
DE69902396T2 (de)	2003-03-20
EE200100140A (et)	2002-06-17
AR022671A1 (es)	2002-09-04
EP1112082B1 (fr)	2002-07-31
JP2002524527A (ja)	2002-08-06
DK1112082T3 (da)	2002-11-25
DE69902396D1 (de)	2002-09-05
KR100699756B1 (ko)	2007-03-27
HUP0103638A2 (hu)	2002-01-28
UA72477C2 (uk)	2005-03-15
KR20010086388A (ko)	2001-09-10
CA2342243A1 (fr)	2000-03-23
JP5270594B2 (ja)	2013-08-21
US8173138B2 (en)	2012-05-08
IS2381B (is)	2008-07-15
EP1112082B2 (fr)	2010-03-17
CN1316906A (zh)	2001-10-10
CN100438905C (zh)	2008-12-03
LT4959B (lt)	2002-10-25
DE69902396T3 (de)	2010-09-30
GEP20032946B (en)	2003-04-25
LV12684A (en)	2001-07-20
NO20011207D0 (no)	2001-03-09
LT2001041A (en)	2002-06-25
JP2007169301A (ja)	2007-07-05
HK1040927A1 (zh)	2002-06-28
HRP20010259A2 (en)	2005-02-28
ZA200101709B (en)	2002-11-28
BR9913585A (pt)	2001-06-05
AU5821499A (en)	2000-04-03
EA200100337A1 (ru)	2001-10-22
NO20011207L (no)	2001-05-09
WO2000015245A2 (fr)	2000-03-23
CA2342243C (fr)	2014-01-14
ES2181473T5 (es)	2010-07-05
CO5170497A1 (es)	2002-06-27
BG105435A (en)	2001-12-29
HUP0103638A3 (en)	2004-06-28
EP1112082A2 (fr)	2001-07-04
PT1112082E (pt)	2002-12-31
JP4557426B2 (ja)	2010-10-06
IS5836A (is)	2001-01-31
AP1591A (en)	2006-03-20

Publication	Publication Date	Title
NO328898B1 (no)	2010-06-07	Stabile, flytende farmasoytiske formuleringer av botulinumtoksin, samt anvendelse derav.
BR9607851B1 (pt)	2009-01-13	combinaÇço e formulaÇço farmacÊutica.
FI952610L (fi)	1995-07-13	Stabiloituja, nestemäisiä entsyymikoostumuksia
BR9712544B1 (pt)	2013-10-22	Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
TR199901077A3 (tr)	1999-12-21	Ispençiyari formülasyonlar.
NO20063000L (no)	1999-12-17	Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
NO981967L (no)	1998-06-30	Stabile fryset°rkede farmas°ytiske formuleringer
DK0853945T3 (da)	2003-08-04	Flydende gonadotropinholdige formuleringer
NO20012915L (no)	2001-08-13	Ny farmasöytisk formulering
NO20004353L (no)	2000-09-01	Nye pyridazinderivater og medikamenter inneholdende disse som aktive ingredienser
BR0014185B1 (pt)	2009-05-05	processos e dispositivos para atomização de lìquidos.
MA26491A1 (fr)	2004-12-20	Composes inhibiteurs selectifs de cox-2, anti-inflammatoires et compositions pharmaceutiques les contenant .
DK1098874T3 (da)	2003-10-06	Benzocycloheptener, fremgangsmåder til deres fremstilling, farmaceutiske præparater, som indeholder disse, samt deres anvendelse til fremstilling af lægemidler
MA26486A1 (fr)	2004-12-20	Aryl- et heteroaryl-thiazolocetohydrazides inhibiteurs de proteases, et compositions pharmaceutiques les contenant .
ID26810A (id)	2001-02-08	Turunan-turunan piridin tersubstitusi n-heteroaril dan penggunannya sebagai herbisida
NO308251B1 (no)	2000-08-21	Karbohydratderivater, farmasøytisk blanding inneholdende karbohydratderivater samt anvendelse av samme
NO984444D0 (no)	1998-09-24	Benzothiofener, formuleringer som inneholder de samme, og fremgangsmÕter
TR199501082A2 (tr)	1996-06-21	Farmasötik formülasyonlar.
NO983802D0 (no)	1998-08-19	Benzothiofener, formuleringer inneholdende samme og fremgangsmÕter
ID27479A (id)	2001-04-12	Turunan piridina dan sediaan farmasinya
NO995838D0 (no)	1999-11-29	Nye heteroetynylenforbindelser og farmasöytiske og kosmetiske preparater inneholdende de samme
PT1033988E (pt)	2004-05-31	Formulacoes parentericas compreendendo 10-hidroxi-10,11-tetra-hidrocarbamazepina agua e glucose
NL1007839A1 (nl)	1998-06-23	Formulering en gebruik.
PT1216021E (pt)	2005-07-29	Composicoes farmaceuticas e/ou cosmeticas
ZA995006B (en)	2000-02-07	Pharmaceutical composition of hedgehog proteins and use thereof.

Legal Events

Date	Code	Title	Description
2001-09-03	RE	Reestablishment of rights (par. 72 patents act)
2012-04-30	MM1K	Lapsed by not paying the annual fees